Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trialLiulu Zhang, Kun Wang, Teng Zhu et al.|Cell Reports Medicine|2025Cited by 9
Abstract PO1-28-08: The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT)Liulu Zhang, Kun Wang, Mei Yang et al.|Cancer Research|2024Cited by 1
Longitudinal Radiomics of Multiparametric MRI to Predict the Risk of Axillary Sentinel Lymph Nodes (SLNs) and Non-SLNs after Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter StudyTeng Zhu, Kun Wang, Yühong Huang et al.|SSRN Electronic Journal|2022Cited by 0
Longitudinal MRI-Based Radiomic Model Assists Sentinel Lymph Node Biopsy to Reduce False Negative Rate after Neoadjuvant Chemotherapy in Initially Clinically Node-Positive Breast Cancer: A Multicentre, Diagnostic StudyTeng Zhu, Kun Wang, Yühong Huang et al.|SSRN Electronic Journal|2023Cited by 0